Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accent MicrocellNSE:ACCENTMIC +1.59%47 EBITDA Margin % is 18.16% as of Mar. 2026, which is 31% above its 10-year median of 13.88. GuruFocus rates NSE:ACCENTMIC with a GF Score™ of 47/100. The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Accent Microcell ranks better than 65.14% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Accent Microcell's EBITDA for the
six
months ended in Mar. 2026 was ₹634 Mil. Accent Microcell's Revenue for the
six
months ended in Mar. 2026 was ₹3,490 Mil. Therefore, Accent Microcell's EBITDA margin for the quarter that ended in Mar. 2026 was 18.16%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Accent Microcell EBITDA Margin % Related Terms
Accent Microcell EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Accent Microcell's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Accent Microcell's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accent Microcell EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accent Microcell's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Accent Microcell's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accent Microcell (NSE:ACCENTMIC) has a EBITDA Margin % of 18.16% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Accent Microcell and its competitors. This is 31% above median its historical median of 13.88. Over the past decade, Accent Microcell's EBITDA Margin % has ranged from 8.76 to 18.24. According to the industry distribution chart, Accent Microcell ranks #334 out of 958 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is Accent Microcell's EBITDA Margin % too high?
Accent Microcell's current EBITDA Margin % of 18.16% is 31% above median its 10-year median of 13.88. Over the past 10 years, this metric has ranged from a low of 8.76 to a high of 18.24. The Drug Manufacturers industry median EBITDA Margin % is 11.93. Accent Microcell's value of 18.16% is 52.2% above this industry median. Based on the distribution chart, Accent Microcell ranks #334 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accent Microcell has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Accent Microcell's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Accent Microcell ranks #334 out of 958 companies for EBITDA Margin %. This puts Accent Microcell in the upper half of its industry. The industry median EBITDA Margin % is 11.93. Accent Microcell's value of 18.16% is 52.2% above this benchmark. Historically, Accent Microcell's own EBITDA Margin % has ranged from 8.76 to 18.24 over the past decade. While the company's 10-year median is 13.88 vs. the industry median of 11.93, Accent Microcell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.93, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accent Microcell's current EBITDA Margin % of 18.16% is 52.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Accent Microcell and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accent Microcell's current EBITDA Margin % is 18.16%, which is 31% above median its own 10-year median of 13.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accent Microcell stock overvalued right now?
Accent Microcell (NSE:ACCENTMIC) has a current EBITDA Margin % of 18.16%. The current EBITDA Margin % is 18.16%, which is 31% above median its 10-year median of 13.88 and 52.2% above the Drug Manufacturers industry median of 11.93. Accent Microcell's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Accent Microcell (NSE:ACCENTMIC), the current EBITDA Margin % is 18.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accent Microcell Ltd is engaged in the manufacturing business of pharmaceutical excipients including products like Microcrystalline Cellulose which is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production; Croscarmellose Sodium used as a super disintegrant in pharmaceutical formulations; Magnesium Stearate; Cellulose Powder, and others. Its business segments are segregated based on the location of its manufacturing facilities and include Dahej (SEZ Unit), Pirana, Unit III, and Inter Unit Sales. Geographically, a majority of the company's revenue is derived through the export of its products to various countries.
47GF Score
Get the complete analysis for NSE:ACCENTMIC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCENTMIC has been successfully added to your 
